Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–88 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone 50 Mg Clear all
Completed Phase 1 Interventional

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

NCT02911597
View directory record Official record
Conditions
Depression
Interventions
Naltrexone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment

NCT00938886
View directory record Official record
Conditions
Hazardous Drinking, Cigarette Smoking
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence

NCT01214083
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
West Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism

NCT00920829
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Naltrexone 50 Mg, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional Results available

Naltrexone Neuroimaging

NCT04935931
View directory record Official record
Conditions
Eating Disorders, Binge Eating, Purging (Eating Disorders)
Interventions
Naltrexone
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Adaptive Goal-Directed Adherence Tracking and Enhancement

NCT01349985
View directory record Official record
Conditions
Alcohol Abuse
Interventions
AGATE, SASED
Other
Lead sponsor
Talaria, Inc
Industry
Eligibility
21 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects

NCT02446002
View directory record Official record
Conditions
Healthy
Interventions
Lofexidine + Naltrexone
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 7, 2026, 2:32 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking

NCT00183222
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

NCT02165930
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Naltrexone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

NCT05090280
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 4 Interventional

Naltrexone, Craving, and Drinking

NCT00006203
View directory record Official record
Conditions
Alcoholism
Interventions
Naltrexone 50 Mg, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

NCT01739192
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
Bupropion
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Naltrexone for Stimulant Abuse

NCT03226223
View directory record Official record
Conditions
Substance Use Disorders, Methamphetamine Abuse
Interventions
Intranasal Methamphetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 7, 2026, 2:32 PM EDT